Gilead Sciences GILD

HealthcareMarket cap $100B3 connections

Gilead Sciences revolutionized HIV treatment with its single-pill regimen Biktarvy - now used by 40%+ of HIV-positive Americans. HIV antiviral sales are so dominant that the disease is now manageable for life in developed countries. Its COVID antiviral Veklury (remdesivir) was the first approved COVID treatment. Its oncology portfolio (Yescarta CAR-T, Trodelvy) is growing rapidly.

Explore Gilead Sciences on the interactive map Relationship timeline Find a path to another company

Suppliers 1

Companies that sell to Gilead Sciences

Alexandria Real EstateReal Estate · $17BLife science real estate

Partners 2

Strategic partnerships, joint products and alliances

Alnylam PharmaHealthcare · $25BCompeting RNA-based rare disease platforms
Nurix TherapeuticsHealthcare · $1BGilead collaboration on targeted protein degraders

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Gilead Sciences's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=GILD" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Gilead Sciences on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.